Search results
Pages
-
- Total dietary antioxidant capacity, individual antioxidant intake and breast cancer risk: The Rotterdam study
-
- Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGF beta receptor I kinase
-
- Healthcare utilisation in patients with breast cancer or non-Hodgkin lymphoma who experienced febrile neutropenia in the Netherlands: a retrospective matched control study using the PHARMO database
-
- Improved overall survival after contralateral risk-reducing mastectomy in brca1/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis
-
- Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: A national cohort study
-
- Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer
-
- Multicenter Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI MSI) Identifies Proteomic Differences in Breast-Cancer-Associated Stroma
-
- Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy
-
- Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma
-
- FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium
-
- Diabetes in relation to breast cancer relapse and all-cause mortality in elderly breast cancer patients: a FOCUS study analysis
-
- Quantitative assessment of lymph vascular space invasion (LVSI) provides important prognostic information in node-negative breast cancer
-
- The impact of next generation sequencing on the analysis of breast cancer susceptibility: a role for extremely rare genetic variation?
-
- Validation, calibration and refitting of a familial breast cancer model in sisterships: a case study in the Swedish sisters data
-
- Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk